A core epitope targeting antibody of SARS-CoV-2
Simeng Zhao(Dalian Medical University), Guisheng Zhong(ShanghaiTech University), Jiabei Wang(University of Science and Technology of China), Lianxin Liu(University of Science and Technology of China), Xiaowen Hu(Lanzhou University), Junzi Ke(ShanghaiTech University), Wei Xu(Beijing Geriatric Hospital), Shizhen Qiu(ShanghaiTech University), Xiuna Yang(ShanghaiTech University), Qiaoshuai Lan(Chinese University of Hong Kong), Shibo Jiang(Shanghai Medical College of Fudan University), Shuai Xia(Shanghai Medical College of Fudan University), Suwen Zhao(Sun Yat-sen University), Hangtian Guo(Nanjing University), Xiaoyan Liu(Capital Medical University), Lu Lu(Shanghai Medical College of Fudan University), Fangfang Zhang(ShanghaiTech University), Youhua Xie(Shanghai Medical College of Fudan University), Haopeng Wang(Guangxi University), Jie Yang(Xijing Hospital), Yiran Wu(Sichuan Research Center of New Materials), Kun Wang(Tongji University), Fengjiang Liu(Guangzhou Experimental Station)
Cited by 0
Related Papers
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
The VSGB 2.0 model: A next generation energy model for high resolution protein structure modeling
|Proteins Structure Function and Bioinformatics|2011|1.1k
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
|RePEc: Research Papers in Economics|0|647
Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
|Nature Communications|2014|400